# Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

> **NCT07094048** · PHASE4 · RECRUITING · sponsor: **CHU de Quebec-Universite Laval** · enrollment: 80 (estimated)

## Conditions studied

- Multiple Myeloma Refractory
- Relapsed Multiple Myeloma

## Interventions

- **DRUG:** Target trough IgG level of 8-10 g/L
- **DRUG:** Target trough IgG level 4-6 g/L
- **DRUG:** No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L

## Key facts

- **NCT ID:** NCT07094048
- **Lead sponsor:** CHU de Quebec-Universite Laval
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-05
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07094048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07094048, "Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07094048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*